



Altimune to Participate in Upcoming Investor Conferences

August 26, 2025 at 7:30 AM EDT

GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:

- **Wells Fargo Healthcare Conference in Boston, MA**
Friday, September 5, 2025
One-on-one meetings only
- **H.C. Wainwright Global Investment Conference in New York, NY**
Tuesday, September 9, 2025
Fireside chat at 8:30 a.m. Eastern Time
The session will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.
- **Morgan Stanley Global Healthcare Conference in New York, NY**
Wednesday, September 10, 2025
Fireside chat at 7:45 a.m. Eastern Time
The session will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [X](#)

Company Contact:

Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contact:

Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Media Contact:

Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
jake.robison@inizioevoke.com

This press release was published by a CLEAR® Verified individual.



Source: Altimune, Inc